We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Arvelle

News List

Ontozry scores MHRA authorisation for focal-onset seizures pharmatimes
June 18, 2021
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted Arvelle Therapeutics’ Ontozry a marketing authorisation (MA) for the adjunctive treatment of focal-onset seizures, with or without secondary generalisation.
Ontozry Receives Positive CHMP Opinion Treatment of Uncontrolled Focal Onset Seizures americanpharmaceuticalreview
February 04, 2021
Arvelle Therapeutics announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of cenobamate for the adjunctive treatment of focal onset seizures with or without secondary ...
SK Biopharmaceuticals-Arvelle partner on epilepsy drug cenobamate in Europe pharmaceutical-technology
February 15, 2019
South Korea-based SK Biopharmaceuticals and Swiss Arvelle Therapeutics have signed an exclusive licensing agreement to develop and commercialise SK Biopharmaceuticals’ cenobamate in Europe....